LANXESS opens 1ast US site for custom manufacturing business
24 Jan '08
3 min read
"The United States is a key center for pharmaceutical innovation, and we're excited about the opportunities this new facility will provide," says Wolfgang Schmitz, Managing Director of Saltigo.
The west coast of the United States is home to many small pharmaceutical companies that can be considered innovation drivers for the entire industry.
For them, cooperation with an experienced and reliable manufacturer is extremely appealing – all the more so when, like Saltigo, the manufacturers also offer wide-ranging services in the analytical and regulatory segments and in project management.
In the medium term, Saltigo expects to establish many new business relationships and thus achieve a corresponding increase in sales.
Saltigo has addressed the increased global demand for CGMP capacities (CGMP – Current Good Manufacturing Practice) in the fine chemicals industry by upgrading a production plant at its integrated site in Leverkusen at a cost of around EUR 10 million.
The existing plant complex has been modified and expanded to create a state-of-the-art multifunctional plant structure for CGMP-compliant production, processing and purification of active ingredients and intermediates. Total capacity of the new facility is more than 200 metric tons a year.
Saltigo GmbH, which is headquartered in Langenfeld and has production facilities in Leverkusen and Dormagen, is a global custom manufacturing specialist.
The three business lines Pharma, Agro and Specialty Chemicals recorded sales of almost EUR 400 million in 2006, making Saltigo one of the leading suppliers in the custom synthesis field.
As a wholly owned subsidiary of the specialty chemicals group LANXESS, Saltigo employs approximately 1,400 people around the globe and combines the flexibility of a medium-sized company with the financial stability and reach of a global player.